LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Gilead Sciences Inc.

Gilead Sciences Inc.

Deschisă

Sector Sănătate

83.12 0.33

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

82.43

Maxim

83.26

Indicatori cheie
By Trading Economics
Venit	5.8B 1.6B
Vânzări	314M 7B
P/E Medie Sector	190.58 103.001
EPS	2.01
Marjă de profit	23.057
Angajați	18,000
EBITDA	6.5B 3B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+0.1 upside

Dividende
By Dow Jones
Următoarele câștiguri	5 nov. 2024
Data viitoare de dividende	27 sept. 2024
Următoarea dată ex-dividende	12 dec. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	99B
Deschiderea anterioară	82.79
Închiderea anterioară	83.12

Sentimentul știrilor

By Acuity

38%

62%

74 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

78.6 / 83.16 Suport & Rezistență

Gilead Sciences Inc. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 aug. 2024, 20:49 UTC

Câștiguri

Gilead Sciences Posts Higher 2Q Profit, Revenue on Increased Sales

25 apr. 2024, 20:39 UTC

Câștiguri

Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges

28 mar. 2024, 13:35 UTC

Principalele dinamici ale pieței

Xilio Shares Take Flight Premarket After Gilead Deal

9 aug. 2024, 20:12 UTC

Câștiguri

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat -- IBD

9 aug. 2024, 09:00 UTC

Top știri

These Stocks Are Moving the Most Today: Expedia, Paramount, E.l.f. Beauty, Doximity, Rocket Lab, Gilead, and More -- Barrons.com

8 aug. 2024, 20:03 UTC

Top știri

Câștiguri

Gilead Boosts Earnings Outlook as Stock Battles Back from Cancer Disappointment -- Barrons.com

8 aug. 2024, 20:03 UTC

Câștiguri

Gilead Sciences Sees FY24 EPS 0c-EPS 30c >GILD

8 aug. 2024, 20:03 UTC

Câștiguri

Gilead Sciences Sees 3Q Adj EPS $3.60-Adj EPS $3.90 >GILD

8 aug. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 2Q Rev $7B >GILD

8 aug. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 2Q Adj EPS $2.01 >GILD

8 aug. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 2Q EPS $1.29 >GILD

8 aug. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 2Q Net $1.61B >GILD

20 iun. 2024, 20:16 UTC

Top știri

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 iun. 2024, 18:09 UTC

Top știri

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 iun. 2024, 16:24 UTC

Câștiguri

Gilead Stock Jumps. Its Twice-Yearly Shot Prevents HIV. -- Barrons.com

20 iun. 2024, 11:00 UTC

Top știri

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

25 apr. 2024, 20:41 UTC

Câștiguri

Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again -- IBD

25 apr. 2024, 20:10 UTC

Câștiguri

Gilead Sciences Cuts FY View To Adj EPS $3.45-Adj EPS $3.85 >GILD

25 apr. 2024, 20:10 UTC

Câștiguri

Gilead Sciences Cuts FY View To EPS 10c-EPS 50c >GILD

25 apr. 2024, 20:09 UTC

Câștiguri

Gilead Sciences Backs FY Product Sales $27.1B-$27.5B >GILD

25 apr. 2024, 20:08 UTC

Câștiguri

Gilead Closed CymaBay Acquisition Resulting in $3.9 B Acquired IPR&D Chg, or $3.14 Diluted EPS Impact

25 apr. 2024, 20:07 UTC

Câștiguri

Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss? -- IBD

25 apr. 2024, 20:03 UTC

Top știri

Câștiguri

Gilead Beats Earnings Expectations After Rocky Quarter -- Barrons.com

25 apr. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Loss $4.17B >GILD

25 apr. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Loss/Shr $3.34 >GILD

25 apr. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Adj Loss/Shr $1.32 >GILD

25 apr. 2024, 20:02 UTC

Câștiguri

Gilead Sciences 1Q Rev $6.7B >GILD

22 mar. 2024, 13:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences Announces Completion Of Acquisition Of CymaBay >GILD CBAY

11 mar. 2024, 12:26 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Other Conditions Remain to Be Satisfied, Including, Among Others, a Minimum Tender of Shrs of Common Stk of CymaBay Representing a Majority of the Total Number of Outstanding Shrs of Common Stk of CymaBay >GILD

11 mar. 2024, 12:26 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Expiration of the HSR Waiting Period Satisfies One of the Conditions to Consummate the Tender Offer >GILD

Comparație

Modificare preț

Gilead Sciences Inc. Așteptări

Obiectiv de preț

By TipRanks

0.1% sus

Prognoză pe 12 luni

Medie 82.89 USD 0.1%

Maxim 95 USD

Minim 70 USD

În baza a 23 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGilead Sciences Inc. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

23 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 23 analiști care au acordat evaluări ale acțiunilor Gilead Sciences Inc. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

78.6 / 83.16Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

74 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Gilead Sciences Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.